Abstract

Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Frequency and Prognostic Significance of Recurrent Gene Mutations in Pediatric B-ALL: Report from the DFCI ALL Consortium
Kara M Kelly ... Marian H Harris
Blood | VOL. 136
Kara M Kelly, et. al.Kara M Kelly ... Marian H Harris
05 Nov 2020
Minimal Residual Disease Monitoring By Next-Generation Sequencing in Patients with Acute Myeloid Leukemia: MRD Positivity after First Consolidation Chemotherapy Can Better Predict Clinical Outcomes Than That after Induction Chemotherapy
Yuan-Yeh Kuo ... Liang-In Lin
Blood | VOL. 134
Yuan-Yeh Kuo, et. al.Yuan-Yeh Kuo ... Liang-In Lin
13 Nov 2019
Comparison of Next-Generation Flow Cytometry (NGF) and Next-Generation Sequencing (NGS) in the Assessment of Minimal Residual Disease in Multiple Myeloma
Weiqin Yao ... Mingqing Zhu
Blood | VOL. 140
Weiqin Yao, et. al.Weiqin Yao ... Mingqing Zhu
15 Nov 2022
Minimal residual disease comparison between Ig/TCR PCR versus NGS assays in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: A report from the COG AALL1631 study.
Ilan Richard Kirsch ... John A Kairalla
Journal of Clinical Oncology | VOL. 40
Ilan Richard Kirsch, et. al.Ilan Richard Kirsch ... John A Kairalla
01 Jun 2022
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.
Luisa Corrêa De Araujo Koury ... Eduardo M Rego
Blood | VOL. -
Luisa Corrêa De Araujo Koury, et. al.Luisa Corrêa De Araujo Koury ... Eduardo M Rego
28 May 2024
Adaptation to ex vivo culture reduces human hematopoietic stem cell activity independently of cell cycle.
Carys S Johnson ... Elisa Laurenti
Blood | VOL. -
Carys S Johnson, et. al.Carys S Johnson ... Elisa Laurenti
28 May 2024
CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models.
Berit J Brinkmann ... Sascha Dietrich
Blood | VOL. -
Berit J Brinkmann, et. al.Berit J Brinkmann ... Sascha Dietrich
28 May 2024
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies
Matthew J Frigault ... Marcela V Maus
Blood | VOL. -
Matthew J Frigault, et. al.Matthew J Frigault ... Marcela V Maus
23 May 2024
View more papers